Oliver Enke1, Heather A New2, Charles H New2, Stephanie Mathieson2, Andrew J McLachlan2, Jane Latimer2, Christopher G Maher2, C-W Christine Lin2. 1. The University of Sydney (Enke, H.A. New, C.H. New), Sydney Medical School Nepean, Kingswood, Australia; Westmead Hospital (H.A. New), Westmead, Australia; The University of Sydney (Mathieson, Latimer, Maher, Lin), Sydney School of Public Health; The University of Sydney and Concord Hospital (McLachlan), Faculty of Pharmacy and Centre for Education and Research on Ageing, Sydney, Australia dr.oliver.enke@gmail.com. 2. The University of Sydney (Enke, H.A. New, C.H. New), Sydney Medical School Nepean, Kingswood, Australia; Westmead Hospital (H.A. New), Westmead, Australia; The University of Sydney (Mathieson, Latimer, Maher, Lin), Sydney School of Public Health; The University of Sydney and Concord Hospital (McLachlan), Faculty of Pharmacy and Centre for Education and Research on Ageing, Sydney, Australia.
Abstract
BACKGROUND: The use of anticonvulsants (e.g., gabapentin, pregabalin) to treat low back pain has increased substantially in recent years despite limited supporting evidence. We aimed to determine the efficacy and tolerability of anticonvulsants in the treatment of low back pain and lumbar radicular pain compared with placebo. METHODS: A search was conducted in 5 databases for studies comparing an anticonvulsant to placebo in patients with nonspecific low back pain, sciatica or neurogenic claudication of any duration. The outcomes were self-reported pain, disability and adverse events. Risk of bias was assessed using the Physiotherapy Evidence Database (PEDro) scale, and quality of evidence was assessed using Grading of Recommendations Assessment, Development and Evaluation (GRADE). Data were pooled and treatment effects were quantified using mean differences for continuous and risk ratios for dichotomous outcomes. RESULTS: Nine trials compared topiramate, gabapentin or pregabalin to placebo in 859 unique participants. Fourteen of 15 comparisons found anticonvulsants were not effective to reduce pain or disability in low back pain or lumbar radicular pain; for example, there was high-quality evidence of no effect of gabapentinoids versus placebo on chronic low back pain in the short term (pooled mean difference [MD] -0.0, 95% confidence interval [CI] -0.8 to 0.7) or for lumbar radicular pain in the immediate term (pooled MD -0.1, 95% CI -0.7 to 0.5). The lack of efficacy is accompanied by increased risk of adverse events from use of gabapentinoids, for which the level of evidence is high. INTERPRETATION: There is moderate- to high-quality evidence that anticonvulsants are ineffective for treatment of low back pain or lumbar radicular pain. There is high-quality evidence that gabapentinoids have a higher risk for adverse events. PROTOCOL REGISTRATION: PROSPERO-CRD42016046363.
BACKGROUND: The use of anticonvulsants (e.g., gabapentin, pregabalin) to treat low back pain has increased substantially in recent years despite limited supporting evidence. We aimed to determine the efficacy and tolerability of anticonvulsants in the treatment of low back pain and lumbar radicular pain compared with placebo. METHODS: A search was conducted in 5 databases for studies comparing an anticonvulsant to placebo in patients with nonspecific low back pain, sciatica or neurogenic claudication of any duration. The outcomes were self-reported pain, disability and adverse events. Risk of bias was assessed using the Physiotherapy Evidence Database (PEDro) scale, and quality of evidence was assessed using Grading of Recommendations Assessment, Development and Evaluation (GRADE). Data were pooled and treatment effects were quantified using mean differences for continuous and risk ratios for dichotomous outcomes. RESULTS: Nine trials compared topiramate, gabapentin or pregabalin to placebo in 859 unique participants. Fourteen of 15 comparisons found anticonvulsants were not effective to reduce pain or disability in low back pain or lumbar radicular pain; for example, there was high-quality evidence of no effect of gabapentinoids versus placebo on chronic low back pain in the short term (pooled mean difference [MD] -0.0, 95% confidence interval [CI] -0.8 to 0.7) or for lumbar radicular pain in the immediate term (pooled MD -0.1, 95% CI -0.7 to 0.5). The lack of efficacy is accompanied by increased risk of adverse events from use of gabapentinoids, for which the level of evidence is high. INTERPRETATION: There is moderate- to high-quality evidence that anticonvulsants are ineffective for treatment of low back pain or lumbar radicular pain. There is high-quality evidence that gabapentinoids have a higher risk for adverse events. PROTOCOL REGISTRATION: PROSPERO-CRD42016046363.
Authors: Stephanie Mathieson; Lisa Valenti; Christopher G Maher; Helena Britt; Qiang Li; Andrew J McLachlan; Chung-Wei Christine Lin Journal: Eur Spine J Date: 2017-06-21 Impact factor: 3.134
Authors: Amir Qaseem; Timothy J Wilt; Robert M McLean; Mary Ann Forciea; Thomas D Denberg; Michael J Barry; Cynthia Boyd; R Dobbin Chow; Nick Fitterman; Russell P Harris; Linda L Humphrey; Sandeep Vijan Journal: Ann Intern Med Date: 2017-02-14 Impact factor: 25.391
Authors: Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann Journal: BMJ Date: 2008-04-26
Authors: Marc-Alexandre Gingras; Anthony Lieu; Louise Papillon-Ferland; Todd C Lee; Emily G McDonald Journal: J Hosp Med Date: 2019-05-12 Impact factor: 2.960
Authors: Lauren R Gorfinkel; Deborah Hasin; Andrew J Saxon; Melanie Wall; Silvia S Martins; Magdalena Cerdá; Katherine Keyes; David S Fink; Salomeh Keyhani; Charles C Maynard; Mark Olfson Journal: J Pain Date: 2022-02-08 Impact factor: 5.383
Authors: Lili Zhou; Sandipan Bhattacharjee; C Kent Kwoh; Daniel C Malone; Patrick J Tighe; Gary M Reisfield; Marion Slack; Debbie L Wilson; Wei-Hsuan Lo-Ciganic Journal: Value Health Date: 2021-01-11 Impact factor: 5.725
Authors: Chang Liu; Christina Abdel Shaheed; Andrew J McLachlan; Jane Latimer; Qiang Li; Rachelle Buchbinder; Richard O Day; Christopher G Maher; Bethan Richards; Juliana S Oliveira; Chung-Wei Christine Lin Journal: BMJ Open Date: 2020-06-23 Impact factor: 2.692
Authors: Raymond Chadwick; Rebekah McNaughton; Sam Eldabe; Ganesan Baranidharan; Jill Bell; Morag Brookes; Rui V Duarte; Jenny Earle; Ashish Gulve; Rachel Houten; Susan Jowett; Anu Kansal; Shelley Rhodes; Jennifer Robinson; Sara Griffiths; Rod S Taylor; Simon Thomson; Harbinder Sandhu Journal: Neuromodulation Date: 2020-12-01